Monopar Therapeutics Inc. (NASDAQ:MNPR – Free Report) – Research analysts at HC Wainwright upped their FY2026 earnings estimates for Monopar Therapeutics in a report issued on Wednesday, January 22nd. HC Wainwright analyst S. Lee now expects that the company will post earnings of $0.70 per share for the year, up from their previous forecast of $0.12. HC Wainwright has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2027 earnings at $2.10 EPS and FY2028 earnings at $3.04 EPS.
Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last issued its earnings results on Friday, November 8th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09.
View Our Latest Analysis on MNPR
Monopar Therapeutics Price Performance
MNPR stock opened at $41.46 on Friday. The business has a 50-day moving average price of $24.65 and a 200 day moving average price of $12.60. The company has a market capitalization of $252.91 million, a P/E ratio of -21.05 and a beta of 1.23. Monopar Therapeutics has a 1-year low of $1.54 and a 1-year high of $41.94.
Insider Transactions at Monopar Therapeutics
In other news, CFO Karthik Radhakrishnan bought 1,550 shares of the company’s stock in a transaction that occurred on Monday, October 28th. The shares were purchased at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the completion of the transaction, the chief financial officer now directly owns 1,550 shares in the company, valued at approximately $25,187.50. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 34.90% of the company’s stock.
About Monopar Therapeutics
Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.
Read More
- Five stocks we like better than Monopar Therapeutics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Bloom Energy: Powering the Future With Decentralized Energy
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul
- About the Markup Calculator
- Why Traders Are Buying the Dip on Johnson & Johnson Stock
Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.